ODC1 (Ornithine Decarboxylase 1) is a rate-limiting enzyme in polyamine biosynthesis, catalyzing the conversion of ornithine to putrescine, a precursor for spermidine and spermine. Polyamines are essential for cell growth, proliferation, and differentiation, making ODC1 critical in cellular homeostasis. Dysregulation of ODC1 is linked to cancer, neurodegenerative diseases, and developmental disorders. Its expression is tightly regulated by oncoproteins like Myc and tumor suppressors, with overexpression observed in various cancers, correlating with poor prognosis.
ODC1 antibodies are vital tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into ODC1's role in cell cycle progression, apoptosis, and tumorigenesis. They also support therapeutic development, as ODC1 inhibition is explored in preclinical cancer models.
Commercially available ODC1 antibodies are typically raised in rabbits or mice against specific epitopes, with validation across species and applications. Challenges include cross-reactivity due to high homology with ODC-like proteins and variable performance in formalin-fixed tissues. Recent studies utilize ODC1 antibodies to investigate its post-translational regulation, including degradation via the 26S proteasome, and its interplay with antiviral responses or metabolic reprogramming in diseases.